Todos Medical Ltd. announced that it signed an amendment to its agreement with its 3CL protease biology theranostics partner NLC Pharma Ltd. As a consequence, NLC Pharma has assigned ownership of all relevant intellectual property to majority-owned joint venture 3CL Pharma Ltd. The assignment includes the patent applications for dual mechanism Phase 2 therapeutic drug candidate Tollovir, commercial-stage 3CL protease inhibitor immune support supplement Tollovid, and 3CL protease biomarker test TolloTest for SARS-CoV-2 infectivity monitoring and PASC/Long COVID viral persistence assessment. 3CL Pharma Ltd. is now preparing to launch a crowdfunding campaign to fund the necessary requirements for an Emergency Use Authorization submission to the US FDA for Tollovir in the treatment of hospitalized COVID-19 patients, the clinical development of Tollovir, Tollovid and TolloTest in Long COVID, as well as a national marketing campaign for Tollovid to support US sales. Todos is targeting a crowdfunding launch ahead of October 6th, 2022 in alignment with the FDA's Adcom meeting for Veru, Inc.'s sabizabulin which is another COVID-19 drug seeking approval in the hospitalized setting.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | 0.00% | 0.00% | -99.50% |
1st Jan change | Capi. | |
---|---|---|
-99.50% | 3.32K | |
-20.45% | 10.82B | |
+43.17% | 3.25B | |
-35.86% | 2.11B | |
-17.21% | 2.08B | |
-29.81% | 1.48B | |
+17.56% | 1.02B | |
-4.37% | 733M | |
-37.00% | 391M | |
-46.94% | 377M |
- Stock Market
- Equities
- TOMDF Stock
- News Todos Medical Ltd.
- Todos Medical, Ltd. Signs to Agreement with Its 3CL Protease Biology Theranostics Partner NLC Pharma, Ltd